PDCD1 and neoplasm: Notably, although HITT overexpression and an anti–PD-1 monoclonal antibody have similar effects on T cell activity, their combination leads to a synergetic effect that inhibits tumor growth and prolongs the survival of mice bearing 4T1 tumors.